SCHEMBL1925656

SCHEMBL1925656

C[C@@H](Nc1c(Nc2ccnc(Nc3ccc(-c4ccncc4)cc3)n2)c(=O)c1=O)C1CCCCC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 19/20 0.65
ROCK2 O75116 2/20 0.65
CHEK2 O96017 2/20 0.65
PIM1 P11309 2/20 0.65
ROCK1 Q13464 2/20 0.65
PLK3 Q9H4B4 2/20 0.65
DAPK3 O43293 1/20 0.65
CDC42BPA Q5VT25 1/20 0.65
AURKB Q96GD4 1/20 0.65
MAPKAPK2 P49137 1/20 0.65
SGK1 O00141 1/20 0.61
PLK4 O00444 1/20 0.61
CHEK1 O14757 1/20 0.61
MAPK13 O15264 1/20 0.61
PDPK1 O15530 1/20 0.61
JAK2 O60674 1/20 0.61
FYN P06241 1/20 0.61
CSF1R P07333 1/20 0.61
MET P08581 1/20 0.61
FLT1 P17948 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1925660 1.00 PLK1 (0.65) PLK1ROCK2CHEK2PIM1ROCK1
SCHEMBL1926504 1.00 PLK1 (0.65) PLK1ROCK2CHEK2PIM1ROCK1
SCHEMBL1926918 0.90 PLK1 (0.55) PLK1ROCK2CHEK2PIM1ROCK1
SCHEMBL1926916 0.90 PLK1 (0.55) PLK1ROCK2CHEK2PIM1ROCK1
SCHEMBL1926869 0.90 PLK1 (0.55) PLK1ROCK2CHEK2PIM1ROCK1
SCHEMBL1926919 0.85 PLK1 (0.52) PLK1ROCK2CHEK2PIM1ROCK1
SCHEMBL1927011 0.85 PLK1 (0.52) PLK1ROCK2CHEK2PIM1ROCK1
SCHEMBL1926921 0.85 PLK1 (0.52) PLK1ROCK2CHEK2PIM1ROCK1
SCHEMBL1926390 0.82 PLK1 (0.65) PLK1ROCK2CHEK2PIM1ROCK1
SCHEMBL4366210 0.80 MAPKAPK2 (1.00) PLK1ROCK2CHEK2PIM1ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7956185-B2 Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinases ABBOTT LABORATORIES (US) 2011-06-07 US claimed
US-7956185-B2 Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinases ABBOTT LABORATORIES (US) 2011-06-07 US disclosed
US-20080015192-A1 INHIBITORS OF POLO-LIKE KINASES ABBVIE INC. 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015192-A1 INHIBITORS OF POLO-LIKE KINASES PLK1, PLK2, BUB1B PLK1 1/4885ROCK2 644/4885CHEK2 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.